相关实验视频
Updated: Sep 15, 2025

05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.3K
动脉样硬化中的纯能受体:对病理生理学和治疗策略的含义
Siarhei A Dabravolski1, Vasily V Kashtalap2, Aleksandra S Utkina3
1Department of Biotechnology Engineering, Braude Academic College of Engineering, Snunit 51, P.O. Box 78, Karmiel, 2161002, Israel. sergedobrowolski@gmail.com.
Journal of physiology and biochemistry
|July 16, 2025
概括
purinergic受体显著影响动脉样硬化发展. 针对特定的P2Y受体提供了一个有希望的治疗策略,以减少血管炎症并改善心血管疾病患者的治疗结果.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 免疫学 免疫学 免疫学
背景情况:
- 动脉样硬化包括脂质积累和动脉壁炎症.
- purinergic受体在动脉样硬化炎症的炎症和细胞过程中起着关键作用.
研究的目的:
- 审查纯能受体在动脉样硬化病理生理学中的作用.
- 为了确定动脉样硬化干预的潜在治疗点.
主要方法:
- 文献审查侧重于P1 (A2A,A3),P2X (P2X4,P2X7) 和P2Y (P2Y2,P2Y11,P2Y12) 受体.
- 综合当前关于动脉样硬化中纯能信号传导的知识.
主要成果:
- A2A/A3受体可以调节炎症和化.
- P2X4 / P2X7受体促进炎症,斑块进展和破裂.
- P2Y2/P2Y11/P2Y12受体参与炎症,化,脂质积累和斑块的形成.
结论:
- P2Y受体对抗剂对动脉样硬化有治疗潜力.
- 需要进一步的研究来将研究结果转化为临床实践,并开发生物标志物.
相关概念视频
Atherosclerosis I: Introduction
92
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
92
Atherosclerosis III: Management
40
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40
Peripheral Artery Disease I: Introduction
35
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
35
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Coronary Artery Disease II: Pathophysiology
40
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
40
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257

